Methods and formulations for the treatment of female sexual dysfunction

Details for Australian Patent Application No. 2002232759 (hide)

Owner Barr Laboratories, Inc.

Inventors Leonard, Thomas, W.; Waldon, R., Waldon

Agent Pizzeys

Pub. Number AU-B-2002232759

PCT Pub. Number WO2002/051420

Priority 60/257,745 22.12.00 US

Filing date 21 December 2001

Wipo publication date 8 July 2002

Acceptance publication date 11 May 2006

International Classifications

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61P 15/12 (2006.01) Drugs for genital or sexual disorders

Event Publications

23 January 2003 Application Open to Public Inspection

  Published as AU-B-2002232759

24 June 2004 Amendment Made

  The nature of the amendment is: Amend the name of the applicant from Endeavor Pharmaceuticals to Endeavor Pharmaceuticals, Inc.

24 June 2004 Assignment before Grant

  Endeavor Pharmaceuticals, Inc. The application has been assigned to Barr Laboratories, Inc.

11 May 2006 Application Accepted

  Published as AU-B-2002232759

7 September 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002232760-Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

2002232758-RECOMBINANT DNA VECTORS FOR EXPRESSION OF SOMATOTROPINS